ArticleTranslational cancer research2026
A novel programmed-cell-death-related prognostic risk model for cervical cancer based on mitochondrial genes.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite established links between mitochondrial (mt) function, programmed cell death (PCD) dysregulation, and cervical cancer progression, the prognostic potential of integrating PCD- with mitochondria-related genes remains elusive. To address this gap, this study aims to develop a reliable RiskScore model leveraging PCD and mt characteristics for cervical cancer prognostic prediction. Methods: mRNA expression profiles with clinical data of 309 cervical cancer patients from The Cancer Genome Atlas (TCGA), complemented by datasets from the Gene Expression Omnibus (GEO) and the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) databases were utilized. We identified differentially expressed genes (DEGs) using the R "limma" package. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis refined gene selection for RiskScore construction. The "rms" package was employed to develop a nomogram model. Additionally, we leveraged generalized structured component analysis (GSCA) for mutation analysis and Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) for immune infiltration assessment. Single-cell sequencing data were processed with the "Seurat" package. Results: Our study identified 119 PCD-related mt DEGs. A prognostic model was developed based on Conclusions: This study introduces a RiskScore model by using PCD-related mt genes for cervical cancer prognosis, offering a personalized therapeutic strategy and insights into immunotherapy potential, potentially advancing future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.